Bio-UV Group SA (FR:ALTUV)
:ALTUV
Want to see FR:ALTUV full AI Analyst Report?
ALTUV Stock Chart & Stats
€1.58
-€0.01(-0.43%)
At close: 4:00 PM EST
€1.58
-€0.01(-0.43%)
Day’s Range― - ―
52-Week Range€1.22 - €2.12
Previous CloseN/A
Volume4.70K
Average Volume (3M)11.56K
Market Cap
€19.09M
Enterprise Value€29.98M
Total Cash (Recent Filing)€10.18M
Total Debt (Recent Filing)€20.23M
Price to Earnings (P/E)25.1
Beta0.38
Next Earnings
Sep 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding14,154,679
10 Day Avg. Volume12,225
30 Day Avg. Volume11,557
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.52
Price to Sales (P/S)0.58
P/FCF Ratio6.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)€38.50M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating cash flow and accelerating free cash flow in 2025 indicate durable cash conversion. This strengthens liquidity, funds maintenance of installed base, supports incremental capex and R&D without frequent external financing, and cushions cyclical downturns.
Manageable Leverage And Stronger EquityDebt-to-equity near mid-single digits historically and a meaningful equity build in 2025 imply balance sheet resilience. Stable assets and lower leverage reduce refinancing risk, give flexibility for selective investments or partnerships, and support multi-year project execution.
Recurring After-sales Revenue ModelA business mix that combines product sales with recurring service, consumables and maintenance creates steady lifetime revenue and higher customer stickiness. This stabilizes cash flows, supports margins over time and enables cross-sell/upgrade economics as installed base grows.
Bears Say
Declining Revenue TrendSustained revenue declines across multiple years weaken operating leverage, compress scale advantages and limit ability to invest in sales, R&D and service expansion. A smaller new-sales funnel risks slowing installed-base growth and reduces long-term recurring revenue potential.
Profitability And Gross Margin VolatilityWide swings in gross profit and uneven EBITDA/net margins reduce earnings predictability and suggest inconsistent cost control or project execution. That volatility undermines planning, makes sustaining margins harder, and raises uncertainty about long-term return on new contracts.
Sizable Absolute Debt And Low ROEAlthough leverage ratios appear manageable, substantial absolute debt obligations increase interest and refinancing exposure. Coupled with low ROE, the balance sheet may struggle to compound shareholder value without stronger earnings recovery, limiting options for large capex or M&A.
Bio-UV Group SA News
ALTUV FAQ
What was Bio-UV Group SA’s price range in the past 12 months?
Bio-UV Group SA lowest stock price was €1.22 and its highest was €2.12 in the past 12 months.
What is Bio-UV Group SA’s market cap?
Bio-UV Group SA’s market cap is €19.09M.
When is Bio-UV Group SA’s upcoming earnings report date?
Bio-UV Group SA’s upcoming earnings report date is Sep 23, 2026 which is in 131 days.
How were Bio-UV Group SA’s earnings last quarter?
Bio-UV Group SA released its earnings results on Apr 08, 2026. The company reported -€0.037 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.037.
Is Bio-UV Group SA overvalued?
According to Wall Street analysts Bio-UV Group SA’s price is currently Overvalued.
Does Bio-UV Group SA pay dividends?
Bio-UV Group SA pays a Annually dividend of €0.06 which represents an annual dividend yield of N/A. See more information on Bio-UV Group SA dividends here
What is Bio-UV Group SA’s EPS estimate?
Bio-UV Group SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-UV Group SA have?
Bio-UV Group SA has 14,154,679 shares outstanding.
What happened to Bio-UV Group SA’s price movement after its last earnings report?
Bio-UV Group SA reported an EPS of -€0.037 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.462%.
Which hedge fund is a major shareholder of Bio-UV Group SA?
Currently, no hedge funds are holding shares in FR:ALTUV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-UV Group SA
Bio-UV Group SA (ALTUV) specializes in the design and manufacturing of advanced disinfection systems utilizing ultraviolet (UV) technology. Operating primarily in the water treatment and sanitation sectors, the company offers a range of products that cater to various applications, including swimming pools, aquaculture, drinking water, and industrial processes. Bio-UV Group is committed to providing eco-friendly solutions that enhance water quality while minimizing environmental impact.
Technical Analysis
Derichebourg
―
Seche Environnement
―
Veolia Environnement
―
Orege SA
―
Groupe Pizzorno Environnement SA
―